Early Fast-Track Versus Standard Care for Persons With HIV Initiating TLD

Status Not yet recruiting

Clinical Trial Summary

This study will evaluate the clinical efficacy of using earlier fast-track services compared to the standard of care in a clinical setting to improve retention in care and virologic suppression for patients who are initiating a dolutegravir-based antiretroviral therapy regimen.

Clinical Trial Description

With current approaches to HIV care, patients generally do not qualify for expedited services until they have been in care for 6 to 12 months. Once they have achieved an undetectable viral load and/or high adherence, patients qualify for expedited services with fewer clinic visits. The problem with this approach is that it's time-intensive early in ART care, when attrition rates are highest. A potential solution to this problem is to provide earlier fast-track care for patients on dolutegravir-based regimens with viral suppression. This strategy is feasible due to the high potency and rapid declines in viral load with dolutegravir-based regimens.

We will compare a strategy of early fast-track care (8 to 12 weeks, for patients with viral suppression) versus standard initiation of fast-track care (after 6 months in care, with viral suppression). All participants will receive the same ART regimen, the combination regimen of Tenofovir Disoproxil Fumarate-Lamivudine-Dolutegravir. ;

Study Design

Related Conditions & MeSH terms

HIV-1-infection

Clinical Trial Details

NCT number	NCT04311944
Study type	Interventional
Source	Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic
Contact	Colette Guiteau, MD
Phone	3449-3596
Email	colette0786@hotmail.com
Status	Not yet recruiting
Phase	N/A
Start date	September 1, 2020
Completion date	May 29, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03940521` - Bioclinical Evaluation of 2 Biomarkers of Aviremic HIV-1 in CD4+ T Cells of Adults Undergoing Treatment
Completed	`NCT03227731` - Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women	Phase 2/Phase 3
Completed	`NCT03570918` - MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy	Phase 1
Not yet recruiting	`NCT06336434` - CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy	Phase 1/Phase 2
Active, not recruiting	`NCT04022967` - ANRS 12372 MODERATO Study	Phase 3
Not yet recruiting	`NCT06282783` - Studying Topiramate for Re-Activating the HIV-1 Reservoir	Phase 1/Phase 2
Not yet recruiting	`NCT06337032` - A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments	Phase 4
Completed	`NCT04711265` - Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys
Recruiting	`NCT03536234` - Efficacy and Safety of GnRH Analogue Triptorelin for HIV-1 Reservoir Reduction in ART Treated HIV-1 Infected Patients	Phase 2
Completed	`NCT04340388` - Contribution of Dolutegravir to Obesity and Cardiovascular Disease	Phase 4
Withdrawn	`NCT05769569` - Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission	Phase 1
Enrolling by invitation	`NCT05584397` - Comparing Immune Activation and Latent HIV Reservoir Size Between People Living With HIV on Tenofovir-containing Versus NRTI-free ART
Completed	`NCT04963712` - Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder	Early Phase 1
Not yet recruiting	`NCT04894357` - Impact of V106I on Resistance to Doravirine
Completed	`NCT04388904` - Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)	Phase 4
Completed	`NCT04568239` - Impact of M184V on the Virological Efficacy to 3TC/DTG (LAMRES)
Not yet recruiting	`NCT04513496` - Telemedicine in HIV Care in Buenos Aires
Not yet recruiting	`NCT04311957` - Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults	Phase 4
Completed	`NCT03998176` - Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE	Phase 4
Completed	`NCT04416906` - A Test and Treat Strategy in New HIV Diagnosis.	Phase 3